Agios Pharmaceuticals, Inc. (AGIO)
| Market Cap | 2.76B |
| Revenue (ttm) | 78.75M |
| Net Income (ttm) | 1.59B |
| Shares Out | 69.94M |
| EPS (ttm) | 23.67 |
| PE Ratio | 1.97 |
| Forward PE | 2.47 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 65,711 |
| Open | 46.98 |
| Previous Close | 46.74 |
| Day's Range | 46.34 - 47.44 |
| 52-Week Range | 32.47 - 62.16 |
| Beta | 1.57 |
| Analysts | Buy |
| Price Target | 62.43 (+33.8%) |
| Est. Earnings Date | Nov 4, 2021 |
About AGIO
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA (enasidenib), an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which...
Financial Performance
In 2020, AGIO's revenue was $203.20 million, an increase of 72.33% compared to the previous year's $117.91 million. Losses were -$327.37 million, -20.44% less than in 2019.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for AGIO stock is "Buy." The 12-month stock price forecast is 62.43, which is an increase of 33.80% from the latest price.
News
Agios To Present at September Investor Conferences
CAMBRIDGE, Mass., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for genetical...
Agios (AGIO) Rare Disease Drug NDA Gets FDA Priority Review
Agios (AGIO) is seeking approval for its lead pipeline candidate, mitapivat, as a potential treatment for PK deficiency.
Agios' Rare Anemia Drug Application Under FDA Priority Review
The FDA has accepted Agios Pharmaceuticals Inc's (NASDAQ: AGIO) marketing application seeking approval for mitapivat for pyruvate kinase (PK) deficiency. Under Priority Review designation, the agency's ...
Agios Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with...
-- PDUFA Date Set for February 17, 2022 -- -- PDUFA Date Set for February 17, 2022 --
Agios' (AGIO) Q2 Loss Narrows, Pipeline Makes Solid Progress
Agios Pharmaceuticals (AGIO) reports narrowed-than-expected loss for the second quarter of 2021. The company did not record any revenue following the oncology portfolio sale.
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Misses Revenue Estimates
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 2.16% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Agios Reports Business Highlights and Second Quarter 2021 Financial Results
– Completed Regulatory Submissions for Mitapivat for the Treatment of Adults with Pyruvate Kinase (PK) Deficiency in the U.S. and EU –
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agios to Webcast Conference Call of Second Quarter 2021 Financial Results on July 29, 2021
CAMBRIDGE, Mass., July 15, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced that t...
Agios (AGIO) Files MAA in EU for Rare Genetic Disease Drug
Agios Pharmaceuticals (AGIO) files a MAA in Europe for its most advanced drug, mitapivat, to treat adults with pyruvate kinase deficiency.
Agios Submits Marketing Authorisation Application to European Medicines Agency for Mitapivat for Treatment of Adults ...
CAMBRIDGE, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for genetical...
Agios (AGIO) Files NDA to FDA for Rare Disease Drug Mitapivat
Agios (AGIO) submits a new drug application to the FDA for its lead candidate, mitapivat, for treating adults with pyruvate kinase deficiency. Stock up.
Agios Launches myAgios® Patient Support Services for Pyruvate Kinase Deficiency
CAMBRIDGE, Mass., June 22, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for genetical...
Agios Pharma Files US Application For Mitapivat In PK Deficiency
Agios Pharmaceuticals Inc (NASDAQ: AGIO) has submitted an FDA marketing application seeking approval for mitapivat to treat adults with pyruvate kinase (PK) deficiency. The company says, if approved, mi...
Agios Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency
CAMBRIDGE, Mass., June 21, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for genetical...
Agios Presents Positive Results from Phase 2 Study of Mitapivat in Non-transfusion-dependent α- and β-Thalassemia at ...
– Study Met Primary Endpoint; Treatment with Mitapivat Induced Hemoglobin Increase of ≥1.0 g/dL in 16 of 20 (80%) Patients During Weeks 4-12 –
Agios Announces Updated Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Defici...
– Company Expects to File for Regulatory Approval for Mitapivat for the Treatment of Adults with PK Deficiency in the U.S. This Quarter and in the EU in Mid-2021 –
Agios to Present Updated Data from Clinical Trials of Mitapivat in Pyruvate Kinase Deficiency and Thalassemia in Oral...
– Agios to Host Investor Webcast on June 11 at 7:30 a.m. ET –
Agios' (AGIO) Q1 Earnings Miss, Pipeline Makes Progress
Agios (AGIO) incurs wider-than-expected loss in the first quarter of 2021. The company fails to record revenues due to the sale of its oncology portfolio including Tibsovo.
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Lags Revenue Estimates
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -6.50% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Agios Reports Business Highlights and First Quarter 2021 Financial Results
– Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency and Phase 2 Study of Mitapivat in Thalassemia Accepted for Presentation at EHA 2021 Virtual Congress –
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.